eligibility_summary
Include: adults ≥18 with biopsy‑proven DLBCL/HGBL/PMBCL/tFL/FL3B, measurable disease, R/R after anti‑CD20+anthracycline chemo, ≥90 d since ASCT/CD19 tx and ≥3 mo post auto CAR‑T, adequate organs, ECOG 0–1, contraception/neg pregnancy test. Exclude: pregnant/lactating, active autoimmune or CNS disease, active infection or HBV/HCV/HIV/HTLV or HHV‑6/7 PCR+, serious cardiac disease, recent anticancer meds/immunosupp/steroids, prior allo/xeno transplant or allo cell therapy, ≥G3 HLH/MAS/neurotox.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: P-CD19CD20-ALLO1, an allogeneic, off-the-shelf CAR-T cell therapy enriched for T stem cell memory (Tscm) cells, single IV dose after lymphodepletion. Rimiducid, a small-molecule chemical dimerizer, may be given as a pharmacologic safety-switch activator for the engineered cells. Mechanisms: P-CD19CD20-ALLO1 T cells express a dual CAR that binds CD19 and CD20 on B cells, triggering T-cell activation, proliferation, and cytotoxic killing of malignant B cells, the Tscm phenotype is intended to enhance persistence and self-renewal. Targets/pathways: cell-surface B-cell antigens CD19 and CD20 on relapsed/refractory DLBCL/HGBCL/PMBCL/tFL/FL3B, lymphodepletion to enable CAR-T expansion, optional rimiducid-responsive apoptosis pathway for rapid CAR-T ablation if needed.